KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.

Ramez N Eskander, Michael W Sill, Lindsey Beffa, Richard G Moore, Joanie M Hope, Fernanda B Musa, Robert S Mannel, Mark S Shahin, Guilherme H Cantuaria, Eugenia Girda, Elizabeth Lokich, Juraj Kavecansky, Charles A Leath, Lilian T Gien, Emily M Hinchcliff, Shashikant B Lele, Lisa M Landrum, Floor Backes, Roisin E O'Cearbhaill, Tareq Al Baghdadi, Emily K Hill, Premal H Thaker, Veena S John, Stephen Welch, Amanda N Fader, Matthew A Powell, Carol Aghajanian

Nat Med 31(5) 1539-1546

PMID40044930
PMCIDPMC12851417
DOI10.1038/s41591-025-03566-1
发表日期2025-03-05
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Historically, the treatment of patients with advanced stage or recurrent endometrial cancer included paclitaxel plus carboplatin. Immunotherapy in combination with chemotherapy resulted in improved clinical outcomes in several solid tumors. In the phase 3 NRG GY018 study, pembrolizumab plus chemotherapy significantly improved investigator-assessed progression-free survival (PFS; primary endpoint) versus placebo plus chemotherapy in patients with advanced/metastatic/recurrent endometrial cancer regardless of mismatch repair status. Here we report on key secondary endpoints and exploratory analyses. Patients were women ≥18 years old with newly diagnosed stage III or IVA endometrial cancer with measurable disease, or stage IVB or recurrent endometrial cancer with or without measurable disease. Patients (n = 810) were randomized (1:1) to pembrolizumab or placebo plus paclitaxel-carboplatin followed by maintenance pembrolizumab or placebo for up to 24 months. Overall survival was a secondary endpoint and PFS per RECIST v.1.1 by blinded independent central review was an exploratory endpoint. Overall survival data were immature; hazard ratios favored pembrolizumab (mismatch repair-proficient: 0.79 (0.53-1.17); 1-sided nominal P = 0.1157; mismatch repair-deficient: 0.55 (0.25-1.19); 1-sided nominal P = 0.0617). Hazard ratios (95% confidence intervals) for PFS per blinded independent central review favored pembrolizumab (mismatch repair-proficient: 0.64 (0.49-0.85); P = 0.0008; mismatch repair-deficient: 0.45 (0.27-0.73); P = 0.0005). These findings further support the use of pembrolizumab plus chemotherapy as first-line treatment for patients with advanced stage or recurrent endometrial cancer regardless of mismatch repair status. ClinicalTrials.gov identifier: NCT03914612 .

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

Extended Data Fig 1.

Kaplan-Meier–estimated PFS per RECIST v1.1 as assessed by the investigators in the dMMR population (A) with methylation and (B) with no methylation at interim analysis. Data cutoff date: December 16, 2022. a Based on a Cox regression model with the Efron method of tie handling with treatment as a covariate. CT, chemotherapy; dMMR, mismatch repair-deficient; HR, hazard ratio; NR, not reached; pembro, pembrolizumab; PFS, progression-free survival; pMMR, mismatch repair-proficient; RECIST, Response Evaluation Criteria in Solid Tumors.

A

Progression-Free Survival

Extended Data Fig 1. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Extended Data Fig 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Progression-Free Survival

Extended Data Fig 1. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Extended Data Fig 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Fig 3.

Kaplan-Meier–estimated OS in the (A) pMMR and (B) dMMR populations at interim analysis. OS data were immature (27.2% information fraction for pMMR population [99/364 events needed for final analysis had occurred] and 18.0% information fraction for dMMR population [27/150 events needed for final analysis had occurred]). Tick marks indicated censored data. Data cutoff dates: December 6, 2022 (pMMR); December 16, 2022 (dMMR). a Follow-up duration is the time from randomization to the date of death or the database cutoff date if the participant is still alive. b Based on a Cox regression model with the Efron method of tie handling with treatment as a covariate stratified by prior chemotherapy. c One-sided P value based on log-rank test stratified by prior chemotherapy. CT, chemotherapy; dMMR, mismatch repair-deficient; HR, hazard ratio; OS, overall survival; NR, not reached; pembro, pembrolizumab; pMMR, mismatch repair-proficient.

A

Overall Survival

Fig 3. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Overall Survival

Fig 3. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(9,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Extended Data Fig 2.Kaplan-Meier–estimated PFS per RECIST v1.1 as assessed by BICR in the (A) pMMR and (B) dMMR populations at interim analysis. Data cutoff dates: December 6, 2022 (pMMR); December 16, 2022 (dMMR). a Based on a Cox regression model with the Efron method of tie handling with treatment as a covariate stratified by prior chemotherapy. b One-sided P value based on log-rank test stratified by prior chemotherapy. CT, chemotherapy; dMMR, mismatch repair-deficient; HR, hazard ratio; NR, not reached; pembro, pembrolizumab; PFS, progression-free survival; pMMR, mismatch repair-proficient; RECIST, Response Evaluation Criteria in Solid Tumors.
非 KM Figure
Extended Data Fig 3.Patient disposition in the pMMR and dMMR populations at ad hoc analysis. Data cutoff date: August 18, 2023. a By central or local immunohistochemistry. b Includes alternative therapy (in absence of progression), off treatment due to other complicating disease, symptomatic deterioration, and other (not otherwise specified). AE, adverse event; dMMR, mismatch repair-deficient; ITT, intention to treat; PD, progressive disease; pMMR, mismatch repair-proficient.
非 KM Figure
Extended Data Fig 4.Kaplan-Meier–estimated OS in the (A) pMMR and (B) dMMR populations and (C) sensitivity analysis in the pMMR population at ad hoc analysis. OS data were immature (46.4% information fraction for pMMR population [169/364 events needed for final analysis had occurred] and 29.3% information fraction for dMMR population [44/150 events needed for final analysis had occurred]). Data cutoff date: August 18, 2023. a Follow-up duration is the time from randomization to the date of death or the database cutoff date if the participant is still alive; follow-up duration was not calculated for the sensitivity analysis (panel C) owing to the nature of the bootstrap analysis. b Based on a Cox regression model with the Efron method of tie handling with treatment as a covariate stratified by prior chemotherapy. c One-sided P value based on log-rank test stratified by prior chemotherapy. CT, chemotherapy; dMMR, mismatch repair-deficient; HR, hazard ratio; NR, not reached; OS, overall survival; pembro, pembrolizumab; pMMR, mismatch repair-proficient.
非 KM Figure
Extended Data Fig 5.Investigator-assessed response rates per RECIST v1.1 at ad hoc analysis in the (A) pMMR and (B) dMMR populations. Analysis included patients in the intention-to-treat population with measurable disease at baseline. Data cutoff date: August 18, 2023. Data shown are the mean ORR and 95% CIs based on the binomial exact method. CR, complete response; CT, chemotherapy; dMMR, mismatch repair-deficient; ORR, objective response rate; pMMR, mismatch repair-proficient; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors.
非 KM Figure
Extended Data Fig 6.Kaplan-Meier–estimated DOR per RECIST v1.1 as assessed by the investigators in the (A) pMMR and (B) dMMR populations at ad hoc analysis. Data cutoff date: August 18, 2023. +, no progressive disease at last disease assessment; CT, chemotherapy; dMMR, mismatch repair-deficient; DOR, duration of response; NR, not reached; pembro, pembrolizumab; pMMR, mismatch repair-proficient; RECIST, Response Evaluation Criteria in Solid Tumors.
非 KM Figure
Extended Data Fig 7.Investigator-assessed best percentage change from baseline in target lesions per RECIST v1.1 in the (A) pMMR and (B) dMMR populations at ad hoc analysis. Data cutoff date: August 18, 2023. CT, chemotherapy; dMMR, mismatch repair-deficient; pembro, pembrolizumab; pMMR, mismatch repair-proficient; RECIST, Response Evaluation Criteria in Solid Tumors.
非 KM Figure
Fig 1.Patient disposition in the pMMR and dMMR populations at interim analysis. Data cutoff dates: December 6, 2022 (pMMR); December 16, 2022 (dMMR). a By central or local immunohistochemistry. b Includes alternative therapy (in absence of progression), off treatment due to other complicating disease, symptomatic deterioration, and other (not otherwise specified). AE, adverse event; dMMR, mismatch repair-deficient; ITT, intention to treat; PD, progressive disease; pMMR, mismatch repair-proficient.
非 KM Figure
Fig 2.Kaplan-Meier–estimated PFS per RECIST v1.1 as assessed by the investigators in the (A) pMMR and (B) dMMR populations at interim analysis. Tick marks indicate censored data. Data cutoff dates: December 6, 2022 (pMMR); December 16, 2022 (dMMR). a Based on a Cox regression model with the Efron method of tie handling with treatment as a covariate stratified by prior chemotherapy. b One-sided P value based on log-rank test stratified by prior chemotherapy. CT, chemotherapy; dMMR, mismatch repair-deficient; HR, hazard ratio; NR, not reached; pembro, pembrolizumab; PFS, progression-free survival; pMMR, mismatch repair-proficient; RECIST, Response Evaluation Criteria in Solid Tumors.
非 KM Figure
Fig 4.Kaplan-Meier–estimated PFS per RECIST v1.1 as assessed by the investigators in subgroups defined by demographics and baseline clinical characteristics in the (A) pMMR population and (B) dMMR population at interim analysis. Results are also shown for the (C) pMMR population with PD-L1 CPS ≥1 tumors, (D) pMMR population with PD-L1 CPS <1 tumors, (E) dMMR population with PD-L1 CPS ≥1 tumors, and (F) dMMR population with PD-L1 CPS <1 tumors at interim analysis. Data shown in panels A and B are the HRs (pembrolizumab plus chemotherapy vs placebo plus chemotherapy) and the corresponding 95% CIs. Data cutoff dates: December 6, 2022 (pMMR); December 16, 2022 (dMMR). Subgroup analyses of PFS were based on an unstratified Cox regression model. CPS was defined as the number of PD-L1−positive cells (tumor cells, lymphocytes, and macrophages) divided by the total number of tumor cells, multiplied by 100. CPS, combined positive score; CT, chemotherapy; dMMR, mismatch repair-deficient; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; NOS, not otherwise specified; NR, not reached; pembro, pembrolizumab; PD-L1, programmed cell death ligand 1; PFS, progression-free survival; pMMR, mismatch repair-proficient; RECIST, Response Evaluation Criteria in Solid Tumors; RT, radiotherapy
非 KM Figure